Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PIK3CA”

158 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 158 results

Testing effectiveness (Phase 2)Ended earlyNCT04216472
What this trial is testing

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+19 more
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT04762979
What this trial is testing

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CarcinomaHER2-negative Breast CancerPIK3CA Mutant Metastatic Breast Cancer
Marina N Sharifi 44
Early research (Phase 1)Study completedNCT05300048
What this trial is testing

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Who this might be right for
Advanced Solid TumorPIK3CA MutationPTEN Loss of Function Mutation
Faeth Therapeutics 34
Testing effectiveness (Phase 2)Ended earlyNCT01602315
What this trial is testing

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma
Novartis Pharmaceuticals 179
Testing effectiveness (Phase 2)Ended earlyNCT02449655
What this trial is testing

Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy

Who this might be right for
Advanced Gastric Adenocarcinoma
Samsung Medical Center 27
Early research (Phase 1)UnknownNCT04856371
What this trial is testing

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Haihe Biopharma Co., Ltd. 228
Early research (Phase 1)Study completedNCT03317119
What this trial is testing

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Who this might be right for
Metastatic Colon CarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Carcinoma+22 more
City of Hope Medical Center 26
Large-scale testing (Phase 3)Active Not RecruitingNCT04191499
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 325
Testing effectiveness (Phase 2)Study completedNCT02428296
What this trial is testing

Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)Growth DisorderGenetics
National Human Genome Research Institute (NHGRI) 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT04544189
What this trial is testing

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Novartis Pharmaceuticals 69
Early research (Phase 1)Looking for participantsNCT05216432
What this trial is testing

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc. 930
Testing effectiveness (Phase 2)Looking for participantsNCT06463028
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Faeth Therapeutics 40
Early research (Phase 1)Study completedNCT01449370
What this trial is testing

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

Who this might be right for
Metastatic Solid Tumors
Millennium Pharmaceuticals, Inc. 125
Testing effectiveness (Phase 2)Ended earlyNCT02644122
What this trial is testing

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Who this might be right for
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Ezra Cohen 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT04524000
What this trial is testing

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 24
Early research (Phase 1)Not Yet RecruitingNCT07383506
What this trial is testing

Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Who this might be right for
PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more
Cogent Biosciences, Inc. 90
Not applicableLooking for participantsNCT07073755
What this trial is testing

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

Who this might be right for
Metastatic Breast CancerDrug ResistanceHormone Receptor-Positive Breast Cancer+3 more
Hunan Cancer Hospital 200
Large-scale testing (Phase 3)Study completedNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Early research (Phase 1)Looking for participantsNCT05683418
What this trial is testing

Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors

Who this might be right for
Squamous Cell Carcinoma of Head and NeckEndometrial CancerHR+/HER2-negative Breast Cancer+1 more
Totus Medicines 241
Early research (Phase 1)Active Not RecruitingNCT05307705
What this trial is testing

LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Who this might be right for
Breast Cancer
Eli Lilly and Company 193
Load More Results